INmune Bio, Inc.

NASDAQ:INMB

Biotechnology

Healthcare
$1.89 +8.38%

+$0.15 today

Market cap
$50.25M
Beta
0.98
P/E (TTM)
-1.1
EPS (TTM)
-$1.56
52W Low $1.09High $3.24

Volume 0.09M

Average 0.68M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$22.58M

FY 2025 · Annual

Investing Cash Flow

-$1.04M

FY 2025 · Annual

Financing Cash Flow

$27.61M

FY 2025 · Annual

+51.6% YoY

Cash Flow Statement

USD
Metric
FY 2021
Dec 2021
FY 2022
Dec 2022
FY 2023
Dec 2023
FY 2024
Dec 2024
FY 2025
Dec 2025
Net Income(30.34M)(27.3M)(30.01M)(42.08M)(45.93M)
Depreciation & Amortization000084K
Deferred Income Tax00000
Stock-Based Compensation4.8M7.15M7.37M7.61M9.91M
Change in Working Capital(3.09M)(2.86M)10.44M1.04M(2.53M)
Accounts Receivables(3.71M)(2.96M)6.02M1.03M(3.13M)
Inventory3.71M2.96M000
Accounts Payables2.26M1.4M2.72M(1.37M)1.86M
Other Working Capital(5.35M)(4.27M)1.7M1.38M(1.25M)
Other Non-Cash Items126K328K224K79K15.89M
Operating Cash Flow(28.5M)(22.69M)(11.98M)(33.36M)(22.58M)
Capital Expenditures(15M)000(1.04M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(15M)000(1.04M)
Debt Repayment14.95M0(5M)(10M)0
Common Stock Issued80.25M699K775K27.79M27.61M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.15M30K0422K0
Financing Cash Flow96.36M729K(4.23M)18.21M27.61M
Effect of Forex Changes(10K)(700K)(100K)224K(159K)
Net Change in Cash52.84M(22.66M)(16.31M)(14.93M)3.83M
Free Cash Flow(43.5M)(22.69M)(11.98M)(33.36M)(23.62M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$45.9M
+ D&A$84.0K
+ Stock-Based Comp$9.9M
+ Deferred Tax$0
- Working Capital-$2.5M
+ Other Non-Cash$15.9M
= Operating Cash Flow-$22.6M
- Capex-$1.0M
= Free Cash Flow-$23.6M

Analysis

FY2025 free cash flow is -$23.6M. FCF conversion is 51.4% of net income. Operating cash flow was -$22.6M, with capex of -$1.0M. The largest bridge item is Other Non-Cash at $15.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
3Initial statement of beneficial ownershipSep 23, 2026
4Statement of changes in beneficial ownershipSep 23, 2026
4Statement of changes in beneficial ownershipSep 17, 2026
3Initial statement of beneficial ownershipSep 16, 2026
8-KCurrent reportSep 14, 2026

Does INMB generate free cash flow?

INmune Bio, Inc. (INMB) generated -$23.62M of free cash flow in fiscal 2025.

How much operating cash flow does INMB produce?

Operating cash flow was -$22.58M, before capital expenditures of $1.04M.